Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer

Aim: Compare lurbinectedin versus other second-line (2L) small-cell lung cancer (SCLC) treatments. 

Methods: An unanchored matching-adjusted indirect comparison connected the platinum-sensitive SCLC cohort of a single-arm lurbinectedin trial to a network of three randomized controlled trials (oral and intravenous [IV] topotecan, and platinum re-challenge) identified by systematic literature review. Network meta-analysis methods estimated relative treatment effects. 

Results: In platinum-sensitive patients, lurbinectedin demonstrated a survival benefit and favorable safety profile versus oral and IV topotecan and platinum re-challenge (overall survival, hazard ratio [HR]: 0.43; 95% credible interval [CrI]: 0.27, 0.67; HR: 0.43; 95% CrI: 0.26, 0.70; HR: 0.42; 95% CrI: 0.30, 0.58 respectively). 

Conclusion: Lurbinectedin showed a robust survival benefit and favorable safety versus other SCLC treatments in 2L platinum-sensitive SCLC.

 

Comments:

Based on the unanchored matching-adjusted indirect comparison, the aim of the study was to compare the efficacy and safety of lurbinectedin with other second-line (2L) treatments for small-cell lung cancer (SCLC). The researchers connected the platinum-sensitive SCLC cohort from a single-arm lurbinectedin trial to a network of three randomized controlled trials that evaluated oral and intravenous (IV) topotecan and platinum re-challenge. The network meta-analysis methods were used to estimate the relative treatment effects.

The results of the analysis showed that in platinum-sensitive SCLC patients, lurbinectedin provided a survival benefit compared to oral and IV topotecan and platinum re-challenge. The hazard ratios (HR) for overall survival were as follows: lurbinectedin versus oral topotecan (HR: 0.43; 95% credible interval [CrI]: 0.27, 0.67), lurbinectedin versus IV topotecan (HR: 0.43; 95% CrI: 0.26, 0.70), and lurbinectedin versus platinum re-challenge (HR: 0.42; 95% CrI: 0.30, 0.58). These results indicate that patients receiving lurbinectedin had a lower risk of death compared to those receiving the other treatments.

Furthermore, lurbinectedin demonstrated a favorable safety profile compared to the other treatments investigated in the study.

In conclusion, based on the findings of this analysis, lurbinectedin exhibited a robust survival benefit and favorable safety profile compared to other second-line treatments for platinum-sensitive SCLC.

Related Products

Cat.No.	Product Name	Information
S9603	Lurbinectedin	Lurbinectedin, a DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity. Lurbinectedin inhibits RMG1 and RMG2 cell growth with IC50 of 1.25 nM and 1.16 nM, respectively.

Related Targets

DNA/RNA Synthesis